^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NT-175
i
Other names: NT-175
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AstraZeneca
Drug class:
TCR modulator, P53 expression modulator
Related drugs:
10ms
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
P1, N=24, Recruiting, Neogene Therapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • NT-175
12ms
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Neogene Therapeutics, Inc.
New P1 trial • Metastases
|
TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
|
cyclophosphamide • NT-175
Share via
